{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:31:02Z","timestamp":1783467062917,"version":"3.55.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"name":"Universiti Sains Malaysia, APEX ERA Grant","award":["R502-KR-ARU004-0000000092-K134"],"award-info":[{"award-number":["R502-KR-ARU004-0000000092-K134"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Ampicillin\u2013sulbactam is the first-line treatment for pneumonia, aspiration pneumonia, and infections caused by\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                      . Several population pharmacokinetic (PK) studies have evaluated the intravenous administration of ampicillin\u2013sulbactam in adults. This systematic review aimed to compare published PK models and identify covariates influencing ampicillin\u2013sulbactam PKs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted using PubMed and Scopus from inception to March 2025. Relevant articles from reference lists were also incorporated. This review included all population PK models of ampicillin\u2013sulbactam administered intravenously in adult patients with various health conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five studies were reviewed, using a two-compartment model for ampicillin\u2013sulbactam. The PK profiles of ampicillin and sulbactam were found to be similar, with comparable CL and V\n                      <jats:sub>d<\/jats:sub>\n                      across all selected studies. Ampicillin clearance ranged from 5.58 to 11.03 L\/h, whereas sulbactam clearance ranged from 4.79 to 10.50 L\/h. The volume of distribution varied from 11.78 to 19.12 L for ampicillin and from 13.89 to 16.77 L for sulbactam. Interindividual variability of ampicillin\u2013sulbactam PK parameters varied across the included studies. Creatinine clearance (CLcr), serum creatinine (SCr), body surface area, body weight, and heart failure were found to be significant covariates affecting the PK parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ampicillin\u2013sulbactam clearance is primarily influenced by renal function (CLcr and SCr) and disease status. None of the studies performed external validation of the developed PK model. This review highlights the PK variability of ampicillin\u2013sulbactam and the need for further research to refine dosing strategies and improve model reliability for clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001380","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T02:00:06Z","timestamp":1756951206000},"page":"60-70","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Models of Ampicillin\u2013Sulbactam Among Adult Patients with Infectious Diseases: A Systematic Review"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2927-5881","authenticated-orcid":false,"given":"Mohananasunthari","family":"Poornachandran","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabariah Noor","family":"Harun","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teh Sin","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Management, Universiti Sains Malaysia, Minden, Penang, Malaysia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noorfatimah","family":"Yahaya","sequence":"additional","affiliation":[{"name":"Advanced Medical and Dental Institute, Universiti Sains Malaysia, Penang, Malaysia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Maisharah","family":"Sheikh Ghadzi","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/antibiotics12020303","article-title":"Pulmonary pharmacokinetic and pharmacodynamic evaluation of ampicillin\/sulbactam regimens for pneumonia caused by various bacteria, including Acinetobacter baumannii","volume":"12","author":"Onita","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1248\/bpb.b20-00781","article-title":"Dosing optimization of ampicillin-sulbactam based on cystatin C in elderly patients with pneumonia","volume":"44","author":"Matsubara","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"suppl 1","key":"R3-20260108","doi-asserted-by":"crossref","first-page":"S732","DOI":"10.1093\/ofid\/ofaa439.1642","article-title":"1461. Impact of the ampicillin\/sulbactam shortage on antibiotic prescribing and clinical outcomes for adult inpatients with aspiration pneumonia","volume":"7","author":"Staicu","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 2","key":"R4-20260108","doi-asserted-by":"crossref","first-page":"ofac492.118","DOI":"10.1093\/ofid\/ofac492.118","article-title":"1652. Sulbactam against Acinetobacter baumannii pneumonia: pharmacokinetic\/pharmacodynamic appraisal of current dosing recommendations","volume":"9","author":"Abouelhassan","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"e00746","DOI":"10.1002\/prp2.746","article-title":"Effects of dosing frequency on the clinical efficacy of ampicillin\/sulbactam in Japanese elderly patients with pneumonia: a single-center retrospective observational study","volume":"9","author":"Suzuki","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7150\/ijms.16090","article-title":"Lower body mass index is a risk factor for in-hospital mortality of elderly Japanese patients treated with ampicillin\/sulbactam","volume":"13","author":"Miura","year":"2016","journal-title":"Int J Med Sci"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"e0124822","DOI":"10.1128\/aac.01248-22","article-title":"Model-informed clinical practice - determining an appropriate ampicillin-sulbactam redosing regimen in surgical patients by utilizing population pharmacokinetics and target attainment analysis","volume":"67","author":"Reeder","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11096-016-0286-5","article-title":"The pharmacokinetics of ampicillin\u2013sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery","volume":"38","author":"Yokoyama","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jcph.1800","article-title":"Prostatic pharmacokinetic\/pharmacodynamic evaluation of ampicillin\u2010sulbactam for bacterial prostatitis and preoperative prophylaxis","volume":"61","author":"Onita","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"suppl 1","key":"R12-20260108","doi-asserted-by":"crossref","first-page":"S670","DOI":"10.1093\/ofid\/ofaa439.1499","article-title":"1317. Pharmacokinetics (PK) of ampicillin-sulbactam (SAM) during orthotopic liver transplantation (OLT)","volume":"7","author":"Lasko","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1248\/bpb.b15-00334","article-title":"Pharmacokinetics of prophylactic ampicillin\u2013sulbactam and dosing optimization in patients undergoing cardiovascular surgery with cardiopulmonary bypass","volume":"38","author":"Yokoyama","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40262-023-01219-5","article-title":"Population pharmacokinetics and dosing simulations of ampicillin and sulbactam in hospitalised adult patients","volume":"62","author":"Setiawan","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12232","article-title":"Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment","volume":"77","author":"Soto","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R18-20260108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jiac.2014.11.006","article-title":"Efficacy and safety of intravenous sulbactam\/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study","volume":"21","author":"Kohno","year":"2015","journal-title":"J Infect Chemother"},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin- sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"issue":"suppl 2","key":"R21-20260108","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin\/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran J Pharm Res"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/cer-2018-0037","article-title":"Meropenem\/colistin versus meropenem\/ampicillin\u2013sulbactam in the treatment of carbapenem-resistant pneumonia","volume":"7","author":"Khalili","year":"2018","journal-title":"J Comp Eff Res"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","article-title":"Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.16335","article-title":"Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice","volume":"91","author":"Berezowska","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17512433.2021.1917377","article-title":"Population pharmacokinetics of oxcarbazepine: a systematic review","volume":"14","author":"Chen","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting guidelines for clinical pharmacokinetic studies: the CLINPK statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-013-0114-1","article-title":"Reporting a population pharmacokinetic\u2013pharmacodynamic study: a journal's perspective","volume":"53","author":"Jamsen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"104940","DOI":"10.1016\/j.ejps.2019.05.018","article-title":"Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii","volume":"136","author":"Jaruratanasirikul","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1128\/AAC.01669-16","article-title":"Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii","volume":"60","author":"Jaruratanasirikul","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jiac.2014.12.005","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections","volume":"21","author":"Yokoyama","year":"2015","journal-title":"J Infect Chemother"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jcph.1650","article-title":"Nonparametric methods in population pharmacokinetics","volume":"62","author":"Goutelle","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"R33-20260108","first-page":"548","article-title":"A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria","volume":"118","author":"Gonz\u00e1lez","year":"1990","journal-title":"Rev Med Chil"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1111\/bcp.15756","article-title":"Using seconds-resolved pharmacokinetic datasets to assess pharmacokinetic models encompassing time\u2010varying physiology","volume":"89","author":"McDonough","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000238765","article-title":"Pharmacokinetics of sulbactam\/ampicillin in humans after intravenous and intramuscular injection","volume":"36","author":"Ripa","year":"1990","journal-title":"Chemotherapy"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/biom15010041","article-title":"The metabolism of creatinine and its usefulness to evaluate kidney function and body composition in clinical practice","volume":"15","author":"\u00c1vila","year":"2025","journal-title":"Biomolecules"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00467-019-04304-9","article-title":"Pharmacokinetics in children with chronic kidney disease","volume":"35","author":"Schijvens","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.18773\/austprescr.2019.054","article-title":"How to adjust drug doses in chronic kidney disease","volume":"42","author":"Stefani","year":"2019","journal-title":"Aust Prescr"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3390\/pharmaceutics16121514","article-title":"Development of a population pharmacokinetic gabapentin model leveraging therapeutic drug monitoring concentrations","volume":"16","author":"Al-Zubaydi","year":"2024","journal-title":"Pharmaceutics"},{"key":"R43-20260108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2013.07.012","article-title":"Ampicillin\/sulbactam: its potential use in treating infections in critically ill patients","volume":"42","author":"Adnan","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","article-title":"Pharmacokinetics and pharmacodynamics of antibacterial agents","volume":"23","author":"Levison","year":"2009","journal-title":"Infect Dis Clin North Am"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"115281","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic alterations associated with critical illness","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003088-199834050-00004","article-title":"Drug interactions at the renal level. implications for drug development","volume":"34","author":"Bonate","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1208\/s12248-012-9407-9","article-title":"Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact","volume":"14","author":"Xu","year":"2012","journal-title":"AAPS J"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1128\/AAC.02414-14","article-title":"Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites","volume":"58","author":"Zhong","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.13760","article-title":"The influence of heart failure on the pharmacokinetics of cardiovascular and non\u2010cardiovascular drugs: a critical appraisal of the evidence","volume":"85","author":"Mangoni","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R52-20260108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bcp.13434","article-title":"Renal function monitoring in heart failure \u2013 what is the optimal frequency? A narrative review","volume":"84","author":"Al\u2010Naher","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"R53-20260108","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/AAC.04132-14","article-title":"Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients","volume":"59","author":"Glatard","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-20260108","doi-asserted-by":"crossref","first-page":"769329","DOI":"10.3389\/fmed.2022.769329","article-title":"Glomerular filtration in the aging population","volume":"9","author":"Noronha","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R55-20260108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R56-20260108","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"key":"R57-20260108","first-page":"397","article-title":"Obesity and chronic kidney disease","volume":"31","author":"Eknoyan","year":"2011","journal-title":"Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia"},{"key":"R58-20260108","doi-asserted-by":"crossref","first-page":"e0171923","DOI":"10.1128\/aac.01719-23","article-title":"Updated antimicrobial dosing recommendations for obese patients","volume":"68","author":"Castro-Balado","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"R59-20260108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R60-20260108","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1208\/s12248-012-9320-2","article-title":"Covariate pharmacokinetic model building in oncology and its potential clinical relevance","volume":"14","author":"Joerger","year":"2012","journal-title":"AAPS J"},{"key":"R61-20260108","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1018828709196","article-title":"The effect of collinearity on parameter estimates in nonlinear mixed effect models","volume":"16","author":"Bonate","year":"1999","journal-title":"Pharm Res"},{"key":"R62-20260108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.12793\/tcp.2019.27.1.19","article-title":"Evolving role of modeling and simulation in drug development","volume":"27","author":"Lim","year":"2019","journal-title":"Transl Clin Pharmacol"},{"key":"R63-20260108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ckj\/sfaa188","article-title":"External validation of prognostic models: what, why, how, when and where?","volume":"14","author":"Ramspek","year":"2021","journal-title":"Clin Kidney J"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:01:39Z","timestamp":1767848499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001380","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"2025-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}